Study explaining side effects of statins finds drug can have unexpected benefits

March 19, 2019

While investigating why cholesterol-lowering drugs called statins cause negative side effects such as blurred vision, short-term memory loss or increased risk for diabetes, cellular chemists at The University of Toledo discovered several previously unknown benefits.

It is well-established statins can help lower the risk of heart attack by lowering blood cholesterol, but statins also may play a protective role in the event of a heart attack because they can suppress a biological process that disrupts cardiac function.

By suppressing the activity of key cellular receptors called G protein-coupled receptors (GPCRs) and their interacting partners called G proteins, statins have the potential to alter various bodily functions controlled by this important pathway, according to research published in the journal Molecular Pharmacology.

"We believe this and our future investigations can help physicians make more informed decisions about prescribing statins, opening a whole new door to what statins can do in addition to cholesterol control," said Dr. Ajith Karunarathne, assistant professor in The University of Toledo Department of Chemistry and Biochemistry.

GPCR signaling pathways are crucial to our survival. They are the largest pharmaceutical drug target - more than one-third of all drugs on the market - because GPCR pathways regulate the body by controlling a variety of functions from vision to heart rate and neurotransmission.

Statins are designed to target and inhibit the cholesterol-synthesis pathway, which is why it is an effective and popular drug to lower cholesterol. But parts of the cholesterol-synthesis pathway are needed for the GPCR signaling pathway to function, which explains the temporary negative side effects while taking statins, such as blurred vision or short-term memory loss.

The UToledo scientists also revealed another crucial finding: The cholesterol-lowering drugs reduce the ability of migratory cells, such as cancer and immune cells, to travel.

When testing GPCR-directed cell invasion, Karunarathne's lab found that statins reduced movement more than 10-fold compared to the control group.

"This indicated that GPCR-governed cancer cell migration also can be reduced by statins," Karunarathne said.

The research was done using cells, not human patients. Karunarathne's lab uses light to control cell behavior - through a novel method named subcellular optogenetics - and studies the way cells respond to light through signal transduction pathways.

"We observed that different types of statins induce very different deviations or changes to G proteins in the GPCR pathway," Mithila Tennakoon, a UToledo Ph.D. student in Karunarathne's lab and first author of the study, said.

"The side effects of statins are not uniform," Karunarathne said. "Cells in the eyes, brain, heart and lungs can have completely different impact levels because they have different types of G proteins."

These findings help explain the molecular sources for side effects of statins, which Karunarathne's lab discovered can have different effects on tissues and organs.
-end-
This research was supported by a grant from the National Institute of General Medical Sciences, part of the National Institutes of Health.

University of Toledo

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.